Dorota Danielak1, Kornel Pawlak2, Franciszek Główka2, Marta Karaźniewicz-Łada2. 1. Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka 3 St, 60-806, Poznań, Poland. danielak@ump.edu.pl. 2. Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka 3 St, 60-806, Poznań, Poland.
Abstract
PURPOSE: P2Y12 receptor inhibitors are drugs that decrease the risk of stent thrombosis and lower the long-term risk of non-stent-related myocardial infarction and stroke. They inhibit the binding of adenosine diphosphate (ADP) to the P2Y12 receptor and effectively reduce platelet reactivity. However, considerable variability in the pharmacodynamics response contributes to a failure of antiplatelet therapy; this phenomenon is especially notorious for older drugs, such as clopidogrel. Some genetic polymorphisms associated with these drugs' metabolic pathway, especially in the CYP2C19 gene, can significantly decrease antiplatelet efficacy. There are few reports on the variability stemming from the target of this drug class that is the P2Y12 receptor itself. RESULTS AND CONCLUSION: This review summarizes the results of research that focus on the influence of P2Y12 genetic polymorphisms on the pharmacodynamics and the efficacy of P2Y12 inhibitors. We found that the conclusions of the studies are unequivocal, and despite several strong candidates, such as G52T (rs6809699) or T744C (rs2046934), they may not be independent predictors of the inadequate response to the drug. Most probably, P2Y12 genetic polymorphisms contribute to the effect exerted by other gene variants (such as CYP2C19*2/*3/*17), drug interactions, or patient habits, such as smoking. Also, epigenetic modifications, such as methylation or miRNA levels, may play a role in the efficacy of antiplatelet treatment.
PURPOSE: P2Y12 receptor inhibitors are drugs that decrease the risk of stent thrombosis and lower the long-term risk of non-stent-related myocardial infarction and stroke. They inhibit the binding of adenosine diphosphate (ADP) to the P2Y12 receptor and effectively reduce platelet reactivity. However, considerable variability in the pharmacodynamics response contributes to a failure of antiplatelet therapy; this phenomenon is especially notorious for older drugs, such as clopidogrel. Some genetic polymorphisms associated with these drugs' metabolic pathway, especially in the CYP2C19 gene, can significantly decrease antiplatelet efficacy. There are few reports on the variability stemming from the target of this drug class that is the P2Y12 receptor itself. RESULTS AND CONCLUSION: This review summarizes the results of research that focus on the influence of P2Y12 genetic polymorphisms on the pharmacodynamics and the efficacy of P2Y12 inhibitors. We found that the conclusions of the studies are unequivocal, and despite several strong candidates, such as G52T (rs6809699) or T744C (rs2046934), they may not be independent predictors of the inadequate response to the drug. Most probably, P2Y12 genetic polymorphisms contribute to the effect exerted by other gene variants (such as CYP2C19*2/*3/*17), drug interactions, or patient habits, such as smoking. Also, epigenetic modifications, such as methylation or miRNA levels, may play a role in the efficacy of antiplatelet treatment.
Authors: Naveen L Pereira; Charanjit Rihal; Ryan Lennon; Gil Marcus; Sanskriti Shrivastava; Malcolm R Bell; Derek So; Nancy Geller; Shaun G Goodman; Ahmed Hasan; Amir Lerman; Yves Rosenberg; Kent Bailey; M Hassan Murad; Michael E Farkouh Journal: JACC Cardiovasc Interv Date: 2021-03-17 Impact factor: 11.195
Authors: Peter Sinnaeve; Gregor Fahrni; Dan Schelfaut; Alessandro Spirito; Christian Mueller; Jean-Marie Frenoux; Abdel Hmissi; Corine Bernaud; Mike Ufer; Tiziano Moccetti; Shaul Atar; Marco Valgimigli Journal: J Am Coll Cardiol Date: 2020-05-26 Impact factor: 24.094
Authors: Kamil F Faridi; Kirk N Garratt; Kevin F Kennedy; Thomas M Maddox; Eric A Secemsky; Neel M Butala; Robert W Yeh Journal: Circ Cardiovasc Qual Outcomes Date: 2020-03-11